An anal fistula or an anorectal fistula as it is also referred to is a type of pathological connection that exists between the anal canal and the adjacent skin and may give rise to the following symptoms: pain, swelling around the anus, bleeding, and discharge of pus. Protheragen is the foremost provider of deep scientific research services and offers integrated preclinical pharmaceutical development and research services for uncommon gastrointestinal disorders such as anal fistula.

Overview of Anal Fistula

The most common occurrence of anal fistula is when the anal glands, located in the intersphincteric plane, get blocked and infected forming a cryptoglandular abscess the development of an anal fistula is possible with surgically or spontaneously drained para rectal abscesses, however, there is a higher chance, 66%, of occurrence with spontaneously draining abscesses. The average incidence reported is 8.6 per 100,000. The existence of acute or chronic anal fistula can be quite troubling for the individuals and impair the quality of life.

Fig.1 Pelvic MRI of anal fistula individual. (You, T., et al., 2023)

Pathogenesis of Anal Fistula

An anal fistula is an epithelialized connection between the anal canal and the external peri-anal region, is formed by inflammatory and granulation tissue, and is associated with Crohn's disease and mucinous adenocarcinoma. The most common culprit for the formation of the anorectal fistula is an infection that is widely believed to stem from an obstruction in the anal glands and crypts. Obstruction of the anal glands leads to bacterial overgrowth and eventually results in an abscess located in the perirectal, anorectal, or perianal region.

Fig.2 The microbiomics properties of anal fistula. (Yang, J., et al., 2024)

Therapeutics Development for Anal Fistula

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Here at Protheragen, our expert team understands the multifaceted problems of rare gastrointestinal disorders face. Our comprehensive approach tackles innovative diagnostic research, advanced therapeutic investigations, sophisticated disease model development, as well as pharmacokinetic studies, and thorough safety assessment of the drug to ensure an accurate shift from preclinical to commercial development.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services for Anal Fistula

Animal models provide a deep understanding of the pathogenesis and management of anal fistula. We employ advanced technologies and systems to design and authenticate animal models while guaranteeing that our preclinical platforms simulate the complexities of anal fistulas with precision.

Given our emphasis on advanced research pertaining to rare gastrointestinal disorders, Protheragen acts as a strategic partner and makes sure that every phase of the drug development cycle is conducted with unyielding scientific rigor. Should you require any of our services, do not hesitate to reach out at your convenience.

References

• You, Ting et al. "A rare anal fistula." Asian journal of surgery 46.10 (2023): 4691-4692.
• Yang, Jun et al. "Microbiomic signatures of anal fistula and putative sources of microbes." Frontiers in cellular and infection microbiology 14 (2024): 1332490.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.